Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

319
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
319
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

214
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
214
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

1.9K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.9K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
Working Memory01:24

Working Memory

453
Working memory refers to a combination of components, including short-term memory and attention, that allow an individual to hold information temporarily as we perform cognitive tasks. It is an essential cognitive function that enables the execution of complex tasks such as problem-solving, comprehension, and reasoning. Unlike short-term memory, which simply involves the storage of information for a brief period, working memory involves the active manipulation and processing of this...
453
Role of Cerebellum and Prefrontal Cortex in Memory01:14

Role of Cerebellum and Prefrontal Cortex in Memory

610
The cerebellum, while traditionally associated with motor control, also plays a crucial role in memory, particularly in procedural memory, which involves learning motor tasks that become automatic through repetition. For example, studies have shown that when the cerebellum is damaged, individuals or animals lose the ability to learn conditioned motor responses, such as the conditioned eye-blink response in classical conditioning experiments with rabbits. This study demonstrates the...
610

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Performance of obstructive sleep apnea screening questionnaires in hospitalized patients with heart failure.

Sleep medicine·2026
Same author

HFE genotype influences substantia nigra iron accumulation and Parkinson's disease progression.

medRxiv : the preprint server for health sciences·2026
Same author

Longitudinal changes of iron in the substantia nigra of early-stage Parkinson's disease.

medRxiv : the preprint server for health sciences·2026
Same author

Levodopa increases substantia nigra iron: implications for Parkinson's disease.

bioRxiv : the preprint server for biology·2026
Same author

Prevalence of GLP-1 Receptor Agonist Use Among Privately Insured Individuals With Mood Disorders.

The Journal of clinical psychiatry·2026
Same author

Insomnia With Objective Short Sleep Duration Is Associated With Incident Cardiovascular and Cerebrovascular Disease: Evidence from the UK Biobank Data.

Journal of the American Heart Association·2026

Related Experiment Video

Updated: Sep 21, 2025

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
10:02

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD

Published on: March 12, 2020

15.9K

A Dopamine D1 Agonist Versus Methylphenidate in Modulating Prefrontal Cortical Working Memory.

Yang Yang1, Mechelle M Lewis2, Lan Kong2

  • 1Department of Pharmacology (Y.Y., M.M.L., R.B.M.), Department of Neurology (M.M.L., R.B.M.), and Department of Public Health Sciences (L.K.), Penn State University College of Medicine, Hershey, Pennsylvania yangyang@psu.edu rmailman@psu.edu.

The Journal of Pharmacology and Experimental Therapeutics
|June 6, 2022
PubMed
Summary

A novel dopamine D1 agonist, 2-methyldihydrexidine, improved spatial working memory (sWM) in rats more effectively than methylphenidate, with fewer side effects. This suggests D1 agonists may be a superior treatment for attention-deficit/hyperactivity disorder (ADHD).

More Related Videos

The 5-Choice Serial Reaction Time Task: A Task of Attention and Impulse Control for Rodents
09:43

The 5-Choice Serial Reaction Time Task: A Task of Attention and Impulse Control for Rodents

Published on: August 10, 2014

46.3K
Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology
07:25

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology

Published on: March 27, 2018

8.7K

Related Experiment Videos

Last Updated: Sep 21, 2025

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
10:02

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD

Published on: March 12, 2020

15.9K
The 5-Choice Serial Reaction Time Task: A Task of Attention and Impulse Control for Rodents
09:43

The 5-Choice Serial Reaction Time Task: A Task of Attention and Impulse Control for Rodents

Published on: August 10, 2014

46.3K
Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology
07:25

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology

Published on: March 27, 2018

8.7K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Behavioral Science

Background:

  • Methylphenidate is a common treatment for attention-deficit/hyperactivity disorder (ADHD), but its stimulant properties cause significant side effects.
  • The precise mechanisms of methylphenidate's action on dopamine and adrenergic receptors are not fully understood.
  • Spatial working memory (sWM) is a key cognitive function affected in ADHD.

Purpose of the Study:

  • To compare the efficacy of methylphenidate with a novel dopamine D1-like receptor agonist, 2-methyldihydrexidine, in a rodent model of sWM.
  • To investigate the neural mechanisms underlying the effects of these compounds on sWM and prefrontal cortex (PFC) activity.
  • To determine if selective D1 receptor targeting offers advantages over methylphenidate for ADHD pharmacotherapy.

Main Methods:

  • Utilized a spontaneously hypertensive rat model to assess sWM performance.
  • Administered methylphenidate and 2-methyldihydrexidine orally and measured their effects on sWM.
  • Investigated the role of the PFC by administering a D1 antagonist (SCH39266) directly into this region.
  • Recorded single-neuron activity in the PFC to correlate neural changes with behavioral outcomes.

Main Results:

  • Methylphenidate improved sWM in only half of the rats, causing impairment in the others; these effects were modulated by PFC D1 receptor blockade.
  • 2-methyldihydrexidine consistently improved sWM without causing impairment, with greater effects in rats with lower baseline performance.
  • Both compounds altered PFC neuronal firing rates, but 2-methyldihydrexidine selectively reduced neuronal preference for improved behavior, while methylphenidate affected impaired behavior retrospectively.

Conclusions:

  • The dopamine D1 receptor agonist 2-methyldihydrexidine demonstrates superior efficacy and a better side-effect profile compared to methylphenidate for enhancing sWM.
  • Neural modulation of the PFC by D1 receptor agonists may represent a more effective therapeutic strategy for ADHD than current stimulant treatments.
  • Selective targeting of the dopamine D1 receptor offers a promising avenue for developing improved ADHD pharmacotherapies.